Trial · NCT00944047
Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
NCT00944047, Phase 2, Completed, University of Kansas Medical Center; results first posted 2018-04-23
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression. Trials, record NCT00944047. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00944047
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression
- NCT number
- NCT00944047
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 32 participants, actual
- Lead sponsor
- University of Kansas Medical Center
- Conditions
- Breast Cancer
- Interventions
- nab-paclitaxel, trastuzumab, Doxorubicin, cyclophosphamide, Growth Factor Support, Surgery
- First posted
- 2009-07-22
- Last updated
- 2018-04-23
- Results first posted
- 2018-04-23
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pathologic Complete Response | 22 weeks |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Pathologic Complete Response | 22 weeks | percentage of participants | NUMBER |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Pathologic Complete Response | Intervention Arm | 26 | percentage of participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Intervention Arm | 32 | |
| Overall Study | COMPLETED | Intervention Arm | 27 | |
| Overall Study | NOT COMPLETED | Intervention Arm | 5 |
Source ClinicalTrials.gov
Adverse events109
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Allergic reaction | Immune system disorders | Intervention Arm | 1 | 32 | 1 |
| other | Rhinitis | Immune system disorders | Intervention Arm | 3 | 32 | 3 |
| other | Otitis, middle | Ear and labyrinth disorders | Intervention Arm | 1 | 32 | 1 |
| other | Blood - Other (Specify) | Blood and lymphatic system disorders | Intervention Arm | 1 | 32 | 1 |
| other | Hemoglobin | Blood and lymphatic system disorders | Intervention Arm | 5 | 32 | 5 |
| other | Leukocytes | Blood and lymphatic system disorders | Intervention Arm | 2 | 32 | 5 |
| other | Neutrophils | Blood and lymphatic system disorders | Intervention Arm | 7 | 32 | 10 |
| other | Palpitations | Cardiac disorders | Intervention Arm | 1 | 32 | 1 |
| other | Sinus tachycardia | Cardiac disorders | Intervention Arm | 1 | 32 | 1 |
| other | Vasovagal episode | Cardiac disorders | Intervention Arm | 1 | 32 | 1 |
1 to 10 of 109Source ClinicalTrials.gov
See all 109 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Intervention Arm | ||
| Total, other adverse events | Intervention Arm | 32 | 32 |
| Total, serious adverse events | Intervention Arm | 5 | 32 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00944047
GET https://conductscience.org/api/trials/v1/NCT00944047/events?page=2